477 Health claim verifications avg. score 5.0/10 172 rated true or mostly true 305 rated false or misleading
“Fruit remains in the human stomach for only about 15 minutes after being eaten.”
The 15-minute figure is not supported by clinical evidence. Whole fruit is a structured, fiber-containing food, not a clear liquid, and standard medical sources describe stomach emptying for solids in hours rather than minutes. Even unusually fast estimates for some fruits are generally above 15 minutes and do not justify a broad claim about all fruit.
“Kūmarahou (Pomaderris kumeraho) does not kill bacteria and is not an antibacterial agent.”
The evidence does not support a categorical claim that kūmarahou lacks antibacterial activity. Published scholarly sources report at least one in vitro study in which crude leaf extracts showed antibacterial effects against Gram-positive bacteria, and other reviews describe preliminary antimicrobial potential. What is not established is clinical effectiveness in humans, not the complete absence of antibacterial activity.
“Triptans should be taken during a migraine attack, not before or after the attack.”
The core advice is correct: triptans are meant for an active migraine attack, not as preventive treatment before one starts or after it has fully ended. Major guidelines and drug labels support use during the headache phase, often with better effect when taken early. The wording is slightly imprecise because triptans can still be taken later in an ongoing attack, and some allow repeat dosing if symptoms return.
“Kūmarahou does not have universally agreed dosage guidelines.”
The evidence supports the claim. Authoritative regulatory and scientific sources do not show any globally or broadly standardized dosage guideline for kūmarahou, while available dosing advice varies across traditional, practitioner, and commercial sources. Some guidance exists, but it is local and non-universal rather than a single agreed standard.
“The gut-brain axis is a real biological communication system between the gastrointestinal tract and the brain.”
The core claim is well supported by mainstream biomedical literature. The gut-brain axis refers to real, bidirectional communication between the gastrointestinal tract and the brain via neural, hormonal, immune, and microbial pathways. What remains unsettled are some specific mechanisms and clinical implications, not the existence of gut-brain communication itself.
“The human gut microbiome produces enough neurotransmitters to directly influence human personality traits and temperament.”
The evidence does not support a direct microbiome-to-personality effect through microbial neurotransmitters. Gut microbes do make neuroactive chemicals, but these generally do not cross into the brain in amounts that would directly shape personality or temperament. Current human research mainly suggests indirect gut-brain signaling and possible links to mood or symptoms, not proven direct control of stable personality traits.
“Most digestive enzymes produced by the small-intestinal wall are bound to the apical (brush-border) cell membrane of intestinal epithelial cells rather than being freely secreted into the intestinal lumen.”
The evidence supports the core claim: small-intestinal digestive enzymes are predominantly brush-border membrane proteins, especially disaccharidases and many peptidases. A minor fraction can be shed into the lumen, and not every enzyme in intestinal cells is brush-border bound, but those caveats do not overturn the main point.
“The study described in PubMed Central article PMCID: PMC12952596 was a randomized clinical trial with a sample of 212 adults.”
The evidence directly supports the claim. PMCID: PMC12952596 is the Make Better Choices 2 study, and the article identifies it as a randomized clinical trial involving 212 adult participants. Independent listings in PubMed, the journal publication, and ClinicalTrials.gov align with that description.
“Pigs are currently the generally accepted source species for xenotransplantation into humans due to their physiological similarity to humans and the ability to scale production.”
Current evidence supports pigs as the accepted source species for human xenotransplantation. The main reasons cited across reviews and clinical updates are functional organ and metabolic compatibility with humans, plus practical scalability through breeding and genetic engineering. The key caveat is that this compatibility is engineered and still faces major immune barriers, so acceptance refers to research and early clinical practice, not routine transplantation.
“There is a real, documented organ shortage crisis.”
The evidence strongly supports the existence of a persistent organ shortage. Official transplant data and peer-reviewed studies show that demand for organs continues to exceed supply, producing large waitlists and ongoing deaths among patients awaiting transplants in both the U.S. and globally. Rising transplant numbers and some improved outcomes indicate progress, not resolution of the shortage.
“In New Zealand, having fewer than 9 deceased organ donors per million people results in hundreds of patients dying each year while waiting for organ transplants.”
The claim is not supported by current New Zealand evidence. Recent official and medical sources place deceased donor rates above 9 per million in many recent years, and the available waiting-list mortality figures are far below “hundreds each year.” Patients do die waiting for transplants, but this claim overstates both the donor-rate problem and the scale of deaths.
“In 2011, there were 400 people on the transplant waiting list in New Zealand.”
The claim is directionally accurate but not exact. The strongest official evidence puts New Zealand’s organ transplant waiting list at 420 people on 31 December 2011, while other sources describe the figure more loosely as about 400 to 500. Saying “400” is a reasonable approximation, but it understates the specific official year-end count and leaves out that the list changed over time.
“Living Cell Technologies conducted clinical trials in New Zealand in which islet cells from Auckland Island pigs were transplanted into eight patients with type 1 diabetes.”
The core description is accurate, but the patient count is incomplete. Reliable sources confirm that Living Cell Technologies conducted New Zealand trials transplanting Auckland Island pig islet cells into people with type 1 diabetes. However, the strongest later evidence reports 14 patients treated overall, so “eight patients” appears to describe only an early cohort, not the full New Zealand trial program.
“Pancreatic proteases such as trypsinogen and chymotrypsinogen are synthesized as inactive zymogens and are activated in the duodenum by an intestinal enzyme (enterokinase/enteropeptidase), which helps prevent autodigestion of the pancreas.”
The claim matches standard human physiology. Pancreatic proteases are secreted as inactive precursors, and enteropeptidase in the duodenum initiates their activation by converting trypsinogen to trypsin, which then activates other zymogens. Delaying activation until the intestine is an important safeguard against pancreatic autodigestion, though not the only one.
“During emulsification in digestion, each microscopic fat droplet contains only fat in its interior, bile salts form a protective outer layer with their lipophilic ends facing inward and hydrophilic ends facing outward, and water is located entirely outside the droplet surrounding it.”
The claim captures the basic orientation of bile salts at a fat-water interface, but it oversimplifies the actual structure of digestive emulsions. In the intestine, droplet surfaces are usually mixed layers of bile salts and phospholipids, and droplet interiors are not strictly pure fat. This is a useful teaching model, not an accurate literal description of every emulsified droplet.
“Consuming sugary drinks before midnight makes babies hyperactive and less likely to fall asleep at their usual bedtime.”
The evidence does not support this claim. Research and pediatric guidance do not show that sugar itself makes babies acutely hyperactive, and the better-supported sleep concern in sweet drinks is caffeine, not sugar alone. The claim also invents a "before midnight" cutoff and extends findings from older children or long-term observational studies to babies and same-night bedtime effects without evidence.
“Reduced perfusion of the small-intestinal mucosa can impair enterocyte renewal and contribute to villous blunting (villous atrophy), reducing absorptive surface area.”
Evidence supports this mechanism. Reduced small-intestinal mucosal perfusion can impair epithelial renewal, promote enterocyte loss, and contribute to villous blunting, which lowers absorptive surface area. The strongest data come from ischemia, shock, and sustained hypoperfusion models, but the claim is appropriately cautious in saying this can occur and can contribute.
“During an acute stress response, splanchnic vasoconstriction reduces gastrointestinal perfusion and prioritizes blood flow to the heart, lungs, and skeletal muscle.”
The statement captures the main physiology: acute sympathetic activation constricts the splanchnic circulation, lowering gastrointestinal blood flow and helping preserve perfusion for the heart and active skeletal muscle. The weak point is "lungs": pulmonary flow usually rises because cardiac output rises, not because blood is selectively diverted there. Many references also emphasize preservation of brain perfusion and arterial pressure.
“Villous blunting can reduce intestinal absorption of nutrients including glucose, amino acids, and fat-soluble vitamins.”
The evidence supports the claim. Villous blunting decreases absorptive surface and functional capacity in the small intestine, which can reduce absorption of glucose, amino acids, and fats; fat-soluble vitamin deficits commonly follow from impaired fat absorption. Severity varies by how extensive the villous damage is, but the basic statement is accurate.
“Physiologic stress can increase intestinal permeability by disrupting tight junctions between enterocytes, which increases translocation of luminal antigens and bacteria.”
The literature strongly supports that stress can impair the intestinal barrier by altering tight-junction function and increasing permeability. Reviews, animal studies, and cell studies also link this barrier disruption to greater passage of luminal antigens and, in some models, bacteria. The main caveat is that the full causal chain is demonstrated most directly in animal and in vitro research; human evidence is stronger for permeability changes than for direct bacterial translocation.